Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mari Mino‐Kenudson, Kurt A. Schalper, Wendy A. Cooper, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 12, pp. 1335-1354
Open Access | Times Cited: 113

Showing 51-75 of 113 citing articles:

Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer
Long Xu, Haojie Si, Fenghui Zhuang, et al.
Journal of Thoracic and Cardiovascular Surgery (2024)
Closed Access | Times Cited: 2
Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma
Haotian Qin, Qichang Wang, Juan Xu, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113282-113282
Closed Access | Times Cited: 2
A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer
Yichao Han, Si‐Yang Maggie Liu, Runsen Jin, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis
Wenyi Yu, Yukun He, Ying Shang, et al.
Clinical Immunology (2023) Vol. 247, pp. 109230-109230
Open Access | Times Cited: 4
Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy—A Systematic Review
Paulina Chmiel, Paulina Rychcik-Pazyrska, Rafał Stec
Cancers (2023) Vol. 15, Iss. 21, pp. 5232-5232
Open Access | Times Cited: 4
Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis
Ting Mei, Quan Zhou, Youling Gong
Clinical Oncology (2023) Vol. 36, Iss. 2, pp. 107-118
Closed Access | Times Cited: 4
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
Jun Miyakoshi, Tatsuya Yoshida, Jumpei Kashima, et al.
Lung Cancer (2024) Vol. 191, pp. 107788-107788
Closed Access | Times Cited: 1
Immunohistochemistry of Lung Cancer Biomarkers
Mary Beth Beasley
Advances in Anatomic Pathology (2024) Vol. 31, Iss. 5, pp. 333-343
Closed Access | Times Cited: 1
Prognostic value of body mass index for first-line chemoimmunotherapy combinations in advanced non-small cell lung cancer in Chinese population
Yanxin Sun, Qi Dang, Yihui Ge, et al.
Heliyon (2024) Vol. 10, Iss. 11, pp. e31863-e31863
Open Access | Times Cited: 1
Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells
Mingyue Liu, Zhangxiang Zhao, Chengyu Wang, et al.
Cancer Letters (2024) Vol. 594, pp. 216991-216991
Closed Access | Times Cited: 1
Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation
Séréna Janho dit Hreich, Olivier Humbert, Tanguy Pace‐Loscos, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2226-2226
Open Access | Times Cited: 1
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors
Giulia Mazzaschi, Fabiana Perrone, Giuseppe Maglietta, et al.
Journal of Immunotherapy (2024) Vol. 47, Iss. 9, pp. 388-394
Open Access | Times Cited: 1
Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer
Chang Qi, Yalun Li, Hao Zeng, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Catriona Rother, Thomas John, Annie Wong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units
Carlo Lazzaro, Giovanni Fattore, Massimo Barberis, et al.
Pathologica (2023) Vol. 115, Iss. 2, pp. 83-89
Open Access | Times Cited: 3
A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC
Francesco Cortiula, Jarushka Naidoo
Lung Cancer (2023) Vol. 181, pp. 107256-107256
Closed Access | Times Cited: 3
Lysosome-related genes: A new prognostic marker for lung adenocarcinoma
Zeyang Hu, Hang Chen, Hongxiang Li, et al.
Medicine (2023) Vol. 102, Iss. 35, pp. e34844-e34844
Open Access | Times Cited: 3
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
Alice Mogenet, Pascal Finetti, Emilie Denicolaï, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 3
The Advanced Practitioner’s Role in the Rapidly Evolving Landscape of Precision Medicine
Donald C. Moore, Andrew S Guinigundo
Journal of the Advanced Practitioner in Oncology (2023) Vol. 14, Iss. 3, pp. 39-48
Open Access | Times Cited: 2
Recent advance of next-generation sequencing in patients with lung cancer
Tianyu Qiu, Xinxin Zhi, Shengxiang Ren
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 11, pp. 959-970
Closed Access | Times Cited: 2
Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort
Paolo Borghetti, Giorgio Facheris, Patrizia Ciammella, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 2, pp. 151-158
Open Access | Times Cited: 2
Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China
Yuxin Wang, Jiahui Lü, Chenxi Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Utilization of cancer immunotherapy in sub-Saharan Africa
Elizabeth Olatunji, Saloni Patel, Katy Graef, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Rethinking the role of biomarkers for operable non-small cell lung carcinoma: an effective collaboration with artificial intelligence algorithms
Esther Conde, Susana Hernández, Fernando López‐Ríos
Modern Pathology (2022) Vol. 35, Iss. 12, pp. 1754-1756
Open Access | Times Cited: 4
TFDP1 is a potential diagnostic, immunological and prognostic biomarker in pan-cancer
Yipeng Zhang, Jie Wang, Guiqian Zhang, et al.
Asian Journal of Surgery (2024) Vol. 47, Iss. 5, pp. 2481-2483
Open Access

Scroll to top